Guideline Review: European Association for the Study of Liver (EASL) Clinical Practice Guidelines on Haemochromatosis
- PMID: 37440950
- PMCID: PMC10333946
- DOI: 10.1016/j.jceh.2022.11.003
Guideline Review: European Association for the Study of Liver (EASL) Clinical Practice Guidelines on Haemochromatosis
Abstract
The European Association for the Study of the Liver (EASL) has recently (June 2022) produced new clinical practice guidelines for the investigation and management of haemochromatosis, to replace the previous document published in 2010. Here, we provide an overview of the principal changes recommended for the investigation and management of haemochromatosis arising from these guidelines and highlight particular areas where evidence is lacking and where future focus on specific research would improve patient treatment and outcomes. The guideline provides several important new recommendations that will have a meaningful impact on patient management. Specifically, the use of hepatic elastography as a non-invasive assessment of fibrosis, erythrocytapheresis as an alternative treatment modality to classical phlebotomy, surveillance for hepatocellular carcinoma, dietary recommendations in patients with haemochromatosis and guidance on controversial topics including the management of P.C282Y/p.H63D compound heterozygotes, which have been a source of controversy within the field. It is anticipated that the new guidance will affect the management of haemochromatosis patients commonly seen in gastroenterology, liver and related clinics (e.g. haematology and rheumatology) and with this publication we intend to highlight these changes so as to empower clinicians with the confidence to bring these improvements to their translational practice in the treatment of these patients.
Keywords: EASL; guideline review; haemochromatosis; liver disease.
© 2022 Indian National Association for Study of the Liver.
Figures
References
-
- Atkins J.L., Pilling L.C., Torti S.V., Torti F.M., Kuchel G.A., Melzer D. Hereditary hemochromatosis variant associations with incident nonliver malignancies: 11-year follow-up in UK Biobank. Cancer Epidemiol biomarkers Prev. 2022 Sep;31:1780–1787. a Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol. - PMC - PubMed
-
- Čuljak M. Hemochromatosis treatment by venipuncture through history. Southeast Eur Med J. 2018;2:44–48.
-
- York Health Economics Consortium & Haemochromatosis UK . 2022. Report : Evaluating the Cost of Illness of Genetic Haemochromatosis in the UK.https://www.haemochromatosis.org.uk/shop/report-evaluating-the-cost-of-i... [Internet] Available from:
Publication types
LinkOut - more resources
Full Text Sources